|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted a retrospective, post-authorized, multicenter study including patients with HER2-positive MBC or locally advanced breast cancer (ABC) treated with the combination of L-T. Concomitant endocrine therapy, as well as brain metastasis and/or prior exposure to L, were allowed.
|
31203575 |
2020 |
|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fulvestrant is a selective oestrogen receptor (ER) degrader used as monotherapy and combination therapy for ER positive HER2 negative advanced breast cancer (ABC) in postmenopausal women.
|
31654283 |
2020 |
|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
Data from 423 human epidermal growth factor receptor 2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes.
|
30536609 |
2019 |
|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pre-treatment prognostic groups with significant differences in OS and PFS for HER2-positive ABC patients initiating second-line and later T-DM1 were identified.
|
31170589 |
2019 |
|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this double-blind, phase 3 study, post-menopausal women with ER+/HER2- ABC who had not received prior systemic therapy for their advanced disease were randomized 2:1 to palbociclib-letrozole or placebo-letrozole.
|
30632023 |
2019 |
|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results confirm that trastuzumab/pertuzumab/taxane is the standard of care as first-line treatment of patients with HER2-positive ABC even in the real-world setting.
|
30403909 |
2019 |
|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
The addition of ribociclib (RIB) to letrozole (LET) significantly increases progression free survival for patients with hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC).
|
30342258 |
2019 |
|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> Pre-treatment prognostic groups identified for HER2-positive ABC patients initiating first-line pertuzumab, trastuzumab, and docetaxel had significantly different long-term disease control and survival outcomes.
|
31508358 |
2019 |
|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
Postmenopausal women with ER+/HER2- ABC were randomly assigned 2:1 to letrozole (2.5 mg daily continuously) plus oral palbociclib (125 mg daily; 3 weeks on/1 week off) or placebo.
|
31217344 |
2019 |
|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this phase 3 study, 666 postmenopausal women with ER+/HER2- ABC were randomized 2:1 to palbociclib (125 mg/day [3 weeks on/1 week off]) plus letrozole (2.5 mg daily) or placebo plus letrozole.
|
30515674 |
2019 |
|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined with demonstrated clinical benefit and tolerability, the stabilization of patient-reported symptoms and HRQoL further supports abemaciclib plus fulvestrant as a desirable treatment option in endocrine resistant, HR+, HER2- ABC.
|
31649135 |
2019 |
|
Bone Cysts, Aneurysmal
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the EMBRACA phase III study (NCT01945775), talazoparib was associated with a significantly prolonged progression-free survival (PFS) compared with physician's choice of chemotherapy (PCT) in germline <i>BRCA1/2</i>-mutated HER2-negative advanced breast cancer (ABC).
|
31767793 |
2019 |
|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three selective CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) have been approved as first-line therapy in combination with an aromatase inhibitor, or fulvestrant in the case of ribociclib in patients with ER+/HER2- ABC.
|
31709685 |
2019 |
|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
MONARCH 2 was a global, randomized, placebo-controlled, double-blind phase 3 trial of abemaciclib plus fulvestrant vs placebo plus fulvestrant for treatment of premenopausal or perimenopausal women (with ovarian suppression) and postmenopausal women with HR-positive, ERBB2-negative ABC that progressed during ET.
|
31563959 |
2019 |
|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
In PALOMA-2, palbociclib + letrozole significantly prolonged progression-free survival (PFS) versus placebo + letrozole in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER<sup>+</sup>/HER2<sup>-</sup>) advanced breast cancer (ABC).
|
31836434 |
2019 |
|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
We retrospectively identified HR-positive HER2-negative ABC patients on the Programme between December 2015 and September 2017.
|
30656459 |
2019 |
|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
A multicenter phase II, prospective study was conducted in anthracyclines and taxanes pre-treated HER2-negative ABC, programmed to receive eribulin as third-line chemotherapy.
|
30734437 |
2019 |
|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
An observational study was conducted in a series of HER2-negative ABC patients treated from January'14-December'17 outside a clinical trial.
|
31753013 |
2019 |
|
Bone Cysts, Aneurysmal
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In early clinical trials, promising disease control benefits were demonstrated with the PI3K isoform-selective inhibitors alpelisib and taselisib in patients with <i>PIK3CA</i>-mutated HR+, HER2- ABC.
|
30651399 |
2019 |
|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
According to the present study, palbociclib plus fulvestrant may be the optimal treatment for HR+/HER2- postmenopausal women with ABC after disease progression following endocrine therapy.
|
30510455 |
2018 |
|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
For example, the significance of inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) in hormone receptor (HR)-positive ABC, of dual antibody blockade in human epidermal growth factor receptor 2 (HER2)-positive ABC, and of poly(ADP-ribose) polymerase (PARP) inhibition in triple-negative ABC, as well as the potential therapeutic consequences, were discussed.
|
29950968 |
2018 |
|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review examines endocrine and endocrine-based options, including combinations with targeted agents, for HR<sup>+</sup> and human epidermal growth factor receptor 2-negative (HER2<sup>-</sup>) ABC.
|
28666813 |
2018 |
|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to evaluate whether PBBPs could have predictive value in HER2-positive ABC treated with pertuzumab and trastuzumab (PT) combined with eribulin (ERI) or nab-paclitaxel (Nab-PTX).
|
30326862 |
2018 |
|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
Postmenopausal women (N = 668) with HR+ , HER2- ABC and no prior systemic therapy for ABC were randomized to RIB (600 mg/day; 3 weeks on/1 week off) plus LET (2.5 mg/day; continuous) or placebo (PBO) plus LET.
|
29404806 |
2018 |
|
Bone Cysts, Aneurysmal
|
0.100 |
Biomarker
|
disease |
BEFREE |
This meta-analysis of randomized controlled trials aimed to comprehensively assess the efficacy and toxicity of cyclin-dependent kinase (CDK) 4/6 inhibitors in advanced breast cancer (ABC) with hormone-receptor positive (HR<sup>+</sup>) and human epidermal growth factor receptor 2 negative (HER2<sup>-</sup>) disease.
|
29804650 |
2018 |